Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Multiple-dose study to access the Safety, tolerability and pharmacokinetics of Ombitasvir/paritaprevir/ritonavir and Dasabuvir in Healthy Han Chinese Subjects residing in USA

Next Previous
Trial Profile

A Phase I, Multiple-dose study to access the Safety, tolerability and pharmacokinetics of Ombitasvir/paritaprevir/ritonavir and Dasabuvir in Healthy Han Chinese Subjects residing in USA

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jul 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 10 Jul 2018 New trial record
    • 16 Jun 2018 Results assessing the Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy and HCV GT1b-Infected Chinese, Korean and Taiwanese Patients from NCT02534870, NCT02517515, NCT02517528 and one more study, published in the European Journal of Drug Metabolism and Pharmacokinetics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top